Bristol Myers Squibb (CELG-RI) Net Cash Flow Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-50.54% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-45.98% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
54.26% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
22.51% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-44.49% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-50.46% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
29.14% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-32.34% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Bristol Myers Squibb |
244.56 Mn |
-10.21 Bn |
8.07 Bn |
-26.50% |
| Date | Value |
|---|
| Mar 31, 2026 |
-26.50% |
| Dec 31, 2025 |
-84.99% |
| Sep 30, 2025 |
45.21% |
| Jun 30, 2025 |
44.84% |
| Mar 31, 2025 |
31.32% |
| Dec 31, 2024 |
74.32% |
| Sep 30, 2024 |
-15.40% |
| Jun 30, 2024 |
-277.98% |
| Mar 31, 2024 |
16.03% |
| Dec 31, 2023 |
40.59% |
| Sep 30, 2023 |
-15.39% |
| Jun 30, 2023 |
-29.10% |
| Mar 31, 2023 |
-27.71% |
| Dec 31, 2022 |
27.49% |
| Sep 30, 2022 |
-50.29% |
| Jun 30, 2022 |
-27.52% |
| Mar 31, 2022 |
-83.19% |
| Dec 31, 2021 |
-31.31% |
| Sep 30, 2021 |
82.64% |
| Jun 30, 2021 |
29.85% |
